Yazar "Esmkhani, Sahra" seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim
    Yayın
    Colorectal cancers and microsatellite instability
    (Türk Radyasyon Onkolojisi Derneği, 2025) Esmkhani, Sahra; Emrem, Mustafa; Şahin, Ali; Babayev, Hüseyn; Zeyneloğlu, Can; Ardıçlı, Sena; Yazıcı, Hilal; Yazıcı, Hülya
    Colorectal cancer (CRC) is a multifactorial disease arising from the complex interplay between genetic predisposition and environmental influences. Despite its widespread incidence globally, CRC demon strates favorable prognostic outcomes when detected at an early stage. Microsatellite instability (MSI) is a common molecular abnormality associated with colorectal tumorigenesis. This review provides a comprehensive analysis of the molecular mechanisms, clinical implications, therapeutic approaches, and immune system interactions in MSI-associated CRC (MSI-CRC). Molecular changes include DNA slippage, dysfunction in the DNA mismatch repair (dMMR) system, and genetic/epigenetic factors that contribute to MSI. Clinically, MSI-CRC is characterized by distinct phenotypic features, including associations with Lynch syndrome, specific diagnostic methodologies, and prognostic relevance. The therapeutic landscape highlights the promising efficacy of immunotherapies and targeted treatments, particularly in dMMR–MSI-H-CRC. Immune dynamics within the tumor microenvironment (TME) reveal patterns of immune infiltration, immune evasion strategies, and opportunities to enhance the effectiveness of immunotherapy. Understanding these interrelated aspects is critical for developing tai lored therapeutic strategies and improving patient outcomes in MSI-CRC
  • Küçük Resim
    Yayın
    New insights of cerium oxide nanoparticles in head and neck cancer treatment
    (Springer Nature, 2025) Tarakçı, Elif; Esmkhani, Sahra; Bayramova, Jamila; Bilgin, Feride Melisa; Kıdık, Kübra; Adıgüzel, Şevin; Tufan, Yiğithan; Yılmaz, Ahsen Morva; Yazıcı, Hülya; Duygulu, Özgür
    Head and neck cancer (HNC) is a genetically complex cancer type having treatment difficulties due to affecting multiple organs in complex anatomical sites. Radiotherapy resistance, chemotoxicity, post-surgery disability makes HNC treatment more complicated. Therefore, there is need to developed new treatment approaches. Nanoparticle-based therapies especially cerium oxide nanoparticles with its anti-cancer features, high catalytic activity, anti- or pro-oxidant and radio-protective properties give a boon for HNC treatment. In the current study, two dextran-coated cerium oxide nanoparticles (Dex-CeNPs) namely SD1 and SD2 were synthesized and characterized by using two types of dextran (D1 and D2) having distinct molecular weights and branching characteristics to understand their potential as a new HNC treatment strategy while evaluating the role of dextran type. The effectivity of the SD1 and SD2 on the HNC cell lines (A253, SCC-25, FaDu) were investigated by analyzing their cytotoxicity, genotoxicity, reactive oxygen species (ROS) generation properties. Low IC50 value, high ROS generation and stability profiling of SD2 compared to SD1 indicates the distinct function of dextran type on Dex-CeNPs effectivity on HNC. To better elucidate the effectivity of SD2, flow cytometry analysis and pro-apoptotic (TP53, CASP3, BAX) and anti-apoptotic (Bcl-2) gene expression profiling were investigated in detail. The findings indicate that SD2 exhibits an influence on head and neck cancer cells via the apoptotic pathway. Our research sets the framework for the development of Dex-CeNPs as remarkable nanotherapeutic candidates for treatment of head and neck cancer.